Vice

Vicebio is a clinical-stage biotechnology company focused on developing next-generation vaccines for life-threatening respiratory viruses. The company's core strength lies in its proprietary Molecular Clamp technology, which stabilizes viral glycoproteins in their pre-fusion state to provoke a more potent and protective immune response. Its lead candidate, VXB-241, is a bivalent vaccine targeting both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV), currently in Phase 1 clinical trials. Based in London and led by former GSK vaccines head Emmanuel Hanon, Vicebio is backed by Medicxi and leverages technology licensed from the University of Queensland. The company aims to address significant unmet needs in infectious disease through highly effective, easy-to-manufacture multivalent vaccines.